PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Equity / Common Stock
Shares outstanding
49,633,071
Total 13F shares
29,741,414
Share change
-1,541,917
Total reported value
$75,860,252
Put/Call ratio
32%
Price per share
$2.55
Number of holders
101
Value change
-$5,783,394
Number of buys
50
Number of sells
40

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2024

As of 30 Sep 2024, PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) was held by 101 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 29,741,414 shares. The largest 10 holders included BlackRock, Inc., VANGUARD GROUP INC, Frazier Life Sciences Management, L.P., MILLENNIUM MANAGEMENT LLC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Eversept Partners, LP, Athyrium Capital Management, LP, GEODE CAPITAL MANAGEMENT, LLC, and AMERICAN CENTURY COMPANIES INC. This page lists 100 institutional shareholders reporting positions in this security for the Q3 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.